Starling Oncology, Inc. Common Stock (STLN) is a publicly traded the market company. As of October 1, 2026, STLN trades at $6.28 with a market cap of $644.11M and a P/E ratio of 0.00. STLN moved -1.58% today. Year to date, STLN is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $4.85 to $7.13. Analyst consensus is strong buy with an average price target of $9.25. Rallies surfaces STLN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for STLN, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $6.28 |
| Market Cap | $644.11M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.13 |
| 52-Week Low | $4.85 |
| Volume | 843.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
4 analysts cover STLN: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.25.